News ·

This week in transparency news: July 7 – July 13, 2018

A small cup filled with assorted pills and capsules

Transparency in clinical trials is continually changing, and to stay on top of the news, TrialAssure brings a weekly round-up of some of the key stories surrounding disclosures in clinical trials. This week’s stories are as follows:

Clinical study registration important for the future of research – National Institute for Health Research (NIHR)

This NIHR blog post by NIHR Operations Director Matt Westmore outlines the importance of study registration, the challenges in registering all studies, and what is on the horizon. Westmore states that some researchers do not register studies for fear of plagiarism, in addition to other reasons like that time it takes to register a study and clarity of the process for niche areas. The author notes that monitoring noncompliance and consolidating information from all research areas is key, but we must carefully consider proper standards and infrastructure.

Read why study registration is important for the future of research.

Standardized funder policies to improve transparency – Medical Bag

Pointing to 2013 expenditure data, this article makes that case that a standard set of clinical trial funder policies would drive greater adherence to transparency obligations. The data notes that half of the funders had policies that required clinical trials to be registered, and calls for greater monitoring of funder policies.

Read more on reducing publication bias in clinical trials.

Upcoming events in clinical trial disclosures

EXL is hosting the 2nd Disclosure and Transparency for Clinical Data Summit on August 13-14, 2018 in Philadelphia, PA. Additional details.

DIA is hosting the Global Clinical Trials Transparency Conference on September 19-20, 2018 in London. More details.

CBI is hosting the 3rd Annual Lay Summaries Summit on September 24-25, 2018 in Philadelphia, PA. More details.

< Back to Blog

Transparent Thinking

Regulatory changes, before they bite

Deadlines, rule changes and practical guidance on clinical trial transparency, in your inbox. No noise.